Revisiting the Safety of Prostaglandin Analog Eyelash Growth Products.

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS

ACS Applied Bio Materials Pub Date : 2021-05-01 DOI:10.1097/DSS.0000000000002928

Kenneth D Steinsapir, Samantha M G Steinsapir

{"title":"Revisiting the Safety of Prostaglandin Analog Eyelash Growth Products.","authors":"Kenneth D Steinsapir, Samantha M G Steinsapir","doi":"10.1097/DSS.0000000000002928","DOIUrl":null,"url":null,"abstract":"Background: The FDA approved bimatoprost ophthalmic solution 0.03% for treatment of eyelash hypotrichosis in 2008. Consumer concern persists regarding potential side effects of this product.Objective: To identify gaps in the safety information associated with the use of prostaglandin eyelash growth products.Materials and methods: Literature searches were performed using PubMed, Embase, and Nexis Uni databases without restriction to publication date, language, or study setting.Results: The literature pertaining to bimatoprost for treatment of eyelash hypotrichosis is dominated by industry-sponsored clinical trials. Study design choices create gaps in our understanding of the clinical safety of these products.Conclusion: Because of study design choice, clinical trials of bimatoprost for eyelash growth may have systematically underreported the incidence of drug application discomfort and prostaglandin-associated periorbitopathy. The risk of increased iris pigmentation remains inadequately investigated. Consequently, there is an ongoing need to educate and monitor patients who choose to use these products.","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":" ","pages":"658-665"},"PeriodicalIF":4.6000,"publicationDate":"2021-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/DSS.0000000000002928","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}

引用次数: 2

Abstract

Background: The FDA approved bimatoprost ophthalmic solution 0.03% for treatment of eyelash hypotrichosis in 2008. Consumer concern persists regarding potential side effects of this product.

Objective: To identify gaps in the safety information associated with the use of prostaglandin eyelash growth products.

Materials and methods: Literature searches were performed using PubMed, Embase, and Nexis Uni databases without restriction to publication date, language, or study setting.

Results: The literature pertaining to bimatoprost for treatment of eyelash hypotrichosis is dominated by industry-sponsored clinical trials. Study design choices create gaps in our understanding of the clinical safety of these products.

Conclusion: Because of study design choice, clinical trials of bimatoprost for eyelash growth may have systematically underreported the incidence of drug application discomfort and prostaglandin-associated periorbitopathy. The risk of increased iris pigmentation remains inadequately investigated. Consequently, there is an ongoing need to educate and monitor patients who choose to use these products.

查看原文本刊更多论文

重新审视前列腺素模拟睫毛生长产品的安全性。

背景:2008年FDA批准了0.03%的比马前列素眼液用于治疗睫毛少毛症。消费者对该产品潜在副作用的担忧持续存在。目的:找出与前列腺素睫毛生长产品使用相关的安全信息的空白。材料和方法:使用PubMed、Embase和Nexis Uni数据库进行文献检索，不受出版日期、语言或研究环境的限制。结果:有关比马前列素治疗睫毛少毛症的文献主要是由行业资助的临床试验。研究设计的选择使我们对这些产品的临床安全性的理解出现空白。结论:由于研究设计的选择，比马前列素用于睫毛生长的临床试验可能系统性地低估了药物应用不适和前列腺素相关的眼周病的发生率。虹膜色素沉着增加的风险仍未得到充分的调查。因此，有必要对选择使用这些产品的患者进行教育和监测。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Applied Bio Materials Chemistry-Chemistry (all)

CiteScore

9.40

自引率

2.10%

发文量

464

期刊介绍： ACS Applied Bio Materials is an interdisciplinary journal publishing original research covering all aspects of biomaterials and biointerfaces including and beyond the traditional biosensing, biomedical and therapeutic applications. The journal is devoted to reports of new and original experimental and theoretical research of an applied nature that integrates knowledge in the areas of materials, engineering, physics, bioscience, and chemistry into important bio applications. The journal is specifically interested in work that addresses the relationship between structure and function and assesses the stability and degradation of materials under relevant environmental and biological conditions.